Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
•
Esophageal Cancer
What dose constraints and how much CTV do you extend into stomach for a patient with a GEJ tumor being treated with pre-operative or definitive chemo-RT?
Related Questions
Does an esophageal stent impact your radiation treatment plan for a patient with non-metastatic GE junction adenocarcinoma?
How would you approach treating a patient who refuses surgery, but has significant residual disease after chemoradiotherapy for squamous cell carcinoma of the esophagus?
For esophageal adenocarcinoma with extensive associated Barrett's, would you extend your CTV coverage beyond the usual expansions to cover the areas of known Barrett's?
For a patient who has T4 squamous cell esophageal carcinoma on imaging, and who has biopsy-confirmed disease in an involved local lymph node, are EUS or EGD still indicated to complete workup?
For a patient with history of sleeve gastrectomy, now diagnosed with GE junction adenocarcinoma, would you alter standard radiation volumes or change your treatment strategy?
How would you alter your treatment volumes in a patient with distal esophageal cancer who has had prior gastric bypass surgery?
For an otherwise resectable esophageal cancer with involved celiac lymph nodes, would you ever consider an SIB beyond 50.4 Gy?
Would you recommend adjuvant capecitabine and radiation in addition to adjuvant FOLFOX for a patient with resected pT3N2 rectosigmoid adenocarcinoma with other high-risk pathologic features?
Do you consider any "favorable" subset of patients with stage IV pancreatic cancer to be candidates for local pre-operative CRT and surgical resection?
Is there a scenario in which you would consider neoadjuvant radiation for rectal cancer after previous definitive radiation for prostate cancer?
